ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Pulmonary Hypertension Drug Market Research Report 2025
Published Date: April 2025
|
Report Code: QYRE-Auto-8M14115
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Chronic Pulmonary Hypertension Drug Market Research Report 2023
BUY CHAPTERS

Global Chronic Pulmonary Hypertension Drug Market Research Report 2025

Code: QYRE-Auto-8M14115
Report
April 2025
Pages:82
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Attgeno
Cereno Scientific
Bial - Portela C S.A
Liquidia Technologies
Bellerophon Therapeutics
AbbVie Therapeutics
Insmed
Altavant Sciences
Lupin Ltd
Sun Pharmaceutical
TEVA

Chronic Pulmonary Hypertension Drug Market Size

The global market for Chronic Pulmonary Hypertension Drug was valued at US$ 6946 million in the year 2024 and is projected to reach a revised size of US$ 9921 million by 2031, growing at a CAGR of 5.3% during the forecast period.

Chronic Pulmonary Hypertension Drug Market

Chronic Pulmonary Hypertension Drug Market

Pulmonary hypertension happens when the pressure in the blood vessels leading from the heart to the lungs is too high. With pulmonary hypertension, the blood vessels to the lungs develop an increased amount of muscle in the wall of the blood vessels.
The chronic pulmonary hypertension drug market is driven by the increasing prevalence of pulmonary hypertension and the growing demand for effective treatment options. Chronic pulmonary hypertension is a progressive and life-threatening condition characterized by high blood pressure in the pulmonary arteries, leading to heart and lung complications. The rise in risk factors such as obesity, cardiovascular diseases, and respiratory disorders contributes to market growth. The development of novel drugs, including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, has significantly improved patient outcomes and expanded treatment options. However, the market also faces challenges, including the complexity of managing the disease, potential side effects of medications, and the need for personalized treatment approaches. Additionally, the high cost of specialized therapies and the limited understanding of the disease"s underlying mechanisms can pose obstacles for both patients and healthcare systems. To succeed, companies must focus on research and development to provide innovative and targeted drug therapies, collaborate with healthcare providers to improve disease management, and address the challenges to meet the increasing demand for effective chronic pulmonary hypertension drugs.
This report aims to provide a comprehensive presentation of the global market for Chronic Pulmonary Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Pulmonary Hypertension Drug.
The Chronic Pulmonary Hypertension Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Pulmonary Hypertension Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Pulmonary Hypertension Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Chronic Pulmonary Hypertension Drug Market Report

Report Metric Details
Report Name Chronic Pulmonary Hypertension Drug Market
Accounted market size in year US$ 6946 million
Forecasted market size in 2031 US$ 9921 million
CAGR 5.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Bayer, Attgeno, Cereno Scientific, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin, Sun Pharmaceutical, Teva
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Chronic Pulmonary Hypertension Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Chronic Pulmonary Hypertension Drug Market growing?

Ans: The Chronic Pulmonary Hypertension Drug Market witnessing a CAGR of 5.3% during the forecast period 2025-2031.

What is the Chronic Pulmonary Hypertension Drug Market size in 2031?

Ans: The Chronic Pulmonary Hypertension Drug Market size in 2031 will be US$ 9921 million.

Who are the main players in the Chronic Pulmonary Hypertension Drug Market report?

Ans: The main players in the Chronic Pulmonary Hypertension Drug Market are Bayer, Attgeno, Cereno Scientific, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin, Sun Pharmaceutical, Teva

What are the Application segmentation covered in the Chronic Pulmonary Hypertension Drug Market report?

Ans: The Applications covered in the Chronic Pulmonary Hypertension Drug Market report are Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Chronic Pulmonary Hypertension Drug Market report?

Ans: The Types covered in the Chronic Pulmonary Hypertension Drug Market report are Oral, Intravenous/Subcutaneous, Inhalational

Recommended Reports

Pulmonary Disease Drugs

Cardiovascular Drugs

Heart & Hypertension

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral
1.2.3 Intravenous/Subcutaneous
1.2.4 Inhalational
1.3 Market by Application
1.3.1 Global Chronic Pulmonary Hypertension Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Pulmonary Hypertension Drug Market Perspective (2020-2031)
2.2 Global Chronic Pulmonary Hypertension Drug Growth Trends by Region
2.2.1 Global Chronic Pulmonary Hypertension Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Pulmonary Hypertension Drug Historic Market Size by Region (2020-2025)
2.2.3 Chronic Pulmonary Hypertension Drug Forecasted Market Size by Region (2026-2031)
2.3 Chronic Pulmonary Hypertension Drug Market Dynamics
2.3.1 Chronic Pulmonary Hypertension Drug Industry Trends
2.3.2 Chronic Pulmonary Hypertension Drug Market Drivers
2.3.3 Chronic Pulmonary Hypertension Drug Market Challenges
2.3.4 Chronic Pulmonary Hypertension Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Pulmonary Hypertension Drug Players by Revenue
3.1.1 Global Top Chronic Pulmonary Hypertension Drug Players by Revenue (2020-2025)
3.1.2 Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Pulmonary Hypertension Drug Revenue
3.4 Global Chronic Pulmonary Hypertension Drug Market Concentration Ratio
3.4.1 Global Chronic Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Pulmonary Hypertension Drug Revenue in 2024
3.5 Global Key Players of Chronic Pulmonary Hypertension Drug Head office and Area Served
3.6 Global Key Players of Chronic Pulmonary Hypertension Drug, Product and Application
3.7 Global Key Players of Chronic Pulmonary Hypertension Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Pulmonary Hypertension Drug Breakdown Data by Type
4.1 Global Chronic Pulmonary Hypertension Drug Historic Market Size by Type (2020-2025)
4.2 Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Type (2026-2031)
5 Chronic Pulmonary Hypertension Drug Breakdown Data by Application
5.1 Global Chronic Pulmonary Hypertension Drug Historic Market Size by Application (2020-2025)
5.2 Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Pulmonary Hypertension Drug Market Size (2020-2031)
6.2 North America Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025)
6.4 North America Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Pulmonary Hypertension Drug Market Size (2020-2031)
7.2 Europe Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025)
7.4 Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size (2020-2031)
8.2 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Pulmonary Hypertension Drug Market Size (2020-2031)
9.2 Latin America Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025)
9.4 Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size (2020-2031)
10.2 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Chronic Pulmonary Hypertension Drug Introduction
11.1.4 Bayer Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.1.5 Bayer Recent Development
11.2 Attgeno
11.2.1 Attgeno Company Details
11.2.2 Attgeno Business Overview
11.2.3 Attgeno Chronic Pulmonary Hypertension Drug Introduction
11.2.4 Attgeno Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.2.5 Attgeno Recent Development
11.3 Cereno Scientific
11.3.1 Cereno Scientific Company Details
11.3.2 Cereno Scientific Business Overview
11.3.3 Cereno Scientific Chronic Pulmonary Hypertension Drug Introduction
11.3.4 Cereno Scientific Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.3.5 Cereno Scientific Recent Development
11.4 Bial - Portela C S.A
11.4.1 Bial - Portela C S.A Company Details
11.4.2 Bial - Portela C S.A Business Overview
11.4.3 Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Introduction
11.4.4 Bial - Portela C S.A Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.4.5 Bial - Portela C S.A Recent Development
11.5 Liquidia Technologies
11.5.1 Liquidia Technologies Company Details
11.5.2 Liquidia Technologies Business Overview
11.5.3 Liquidia Technologies Chronic Pulmonary Hypertension Drug Introduction
11.5.4 Liquidia Technologies Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.5.5 Liquidia Technologies Recent Development
11.6 Bellerophon Therapeutics
11.6.1 Bellerophon Therapeutics Company Details
11.6.2 Bellerophon Therapeutics Business Overview
11.6.3 Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Introduction
11.6.4 Bellerophon Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.6.5 Bellerophon Therapeutics Recent Development
11.7 AbbVie Therapeutics
11.7.1 AbbVie Therapeutics Company Details
11.7.2 AbbVie Therapeutics Business Overview
11.7.3 AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Introduction
11.7.4 AbbVie Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.7.5 AbbVie Therapeutics Recent Development
11.8 Insmed
11.8.1 Insmed Company Details
11.8.2 Insmed Business Overview
11.8.3 Insmed Chronic Pulmonary Hypertension Drug Introduction
11.8.4 Insmed Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.8.5 Insmed Recent Development
11.9 Altavant Sciences
11.9.1 Altavant Sciences Company Details
11.9.2 Altavant Sciences Business Overview
11.9.3 Altavant Sciences Chronic Pulmonary Hypertension Drug Introduction
11.9.4 Altavant Sciences Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.9.5 Altavant Sciences Recent Development
11.10 Lupin
11.10.1 Lupin Company Details
11.10.2 Lupin Business Overview
11.10.3 Lupin Chronic Pulmonary Hypertension Drug Introduction
11.10.4 Lupin Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.10.5 Lupin Recent Development
11.11 Sun Pharmaceutical
11.11.1 Sun Pharmaceutical Company Details
11.11.2 Sun Pharmaceutical Business Overview
11.11.3 Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Introduction
11.11.4 Sun Pharmaceutical Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.11.5 Sun Pharmaceutical Recent Development
11.12 Teva
11.12.1 Teva Company Details
11.12.2 Teva Business Overview
11.12.3 Teva Chronic Pulmonary Hypertension Drug Introduction
11.12.4 Teva Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025)
11.12.5 Teva Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Bayer
Attgeno
Cereno Scientific
Bial - Portela C S.A
Liquidia Technologies
Bellerophon Therapeutics
AbbVie Therapeutics
Insmed
Altavant Sciences
Lupin Ltd
Sun Pharmaceutical
TEVA
List of Tables
 Table 1. Global Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Oral
 Table 3. Key Players of Intravenous/Subcutaneous
 Table 4. Key Players of Inhalational
 Table 5. Global Chronic Pulmonary Hypertension Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Chronic Pulmonary Hypertension Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Chronic Pulmonary Hypertension Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Chronic Pulmonary Hypertension Drug Market Share by Region (2020-2025)
 Table 9. Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Chronic Pulmonary Hypertension Drug Market Share by Region (2026-2031)
 Table 11. Chronic Pulmonary Hypertension Drug Market Trends
 Table 12. Chronic Pulmonary Hypertension Drug Market Drivers
 Table 13. Chronic Pulmonary Hypertension Drug Market Challenges
 Table 14. Chronic Pulmonary Hypertension Drug Market Restraints
 Table 15. Global Chronic Pulmonary Hypertension Drug Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Chronic Pulmonary Hypertension Drug Market Share by Players (2020-2025)
 Table 17. Global Top Chronic Pulmonary Hypertension Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Pulmonary Hypertension Drug as of 2024)
 Table 18. Ranking of Global Top Chronic Pulmonary Hypertension Drug Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Chronic Pulmonary Hypertension Drug Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Chronic Pulmonary Hypertension Drug, Headquarters and Area Served
 Table 21. Global Key Players of Chronic Pulmonary Hypertension Drug, Product and Application
 Table 22. Global Key Players of Chronic Pulmonary Hypertension Drug, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Chronic Pulmonary Hypertension Drug Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Type (2020-2025)
 Table 26. Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Type (2026-2031)
 Table 28. Global Chronic Pulmonary Hypertension Drug Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Application (2020-2025)
 Table 30. Global Chronic Pulmonary Hypertension Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Chronic Pulmonary Hypertension Drug Revenue Market Share by Application (2026-2031)
 Table 32. North America Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Bayer Company Details
 Table 48. Bayer Business Overview
 Table 49. Bayer Chronic Pulmonary Hypertension Drug Product
 Table 50. Bayer Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 51. Bayer Recent Development
 Table 52. Attgeno Company Details
 Table 53. Attgeno Business Overview
 Table 54. Attgeno Chronic Pulmonary Hypertension Drug Product
 Table 55. Attgeno Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 56. Attgeno Recent Development
 Table 57. Cereno Scientific Company Details
 Table 58. Cereno Scientific Business Overview
 Table 59. Cereno Scientific Chronic Pulmonary Hypertension Drug Product
 Table 60. Cereno Scientific Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 61. Cereno Scientific Recent Development
 Table 62. Bial - Portela C S.A Company Details
 Table 63. Bial - Portela C S.A Business Overview
 Table 64. Bial - Portela C S.A Chronic Pulmonary Hypertension Drug Product
 Table 65. Bial - Portela C S.A Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 66. Bial - Portela C S.A Recent Development
 Table 67. Liquidia Technologies Company Details
 Table 68. Liquidia Technologies Business Overview
 Table 69. Liquidia Technologies Chronic Pulmonary Hypertension Drug Product
 Table 70. Liquidia Technologies Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 71. Liquidia Technologies Recent Development
 Table 72. Bellerophon Therapeutics Company Details
 Table 73. Bellerophon Therapeutics Business Overview
 Table 74. Bellerophon Therapeutics Chronic Pulmonary Hypertension Drug Product
 Table 75. Bellerophon Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 76. Bellerophon Therapeutics Recent Development
 Table 77. AbbVie Therapeutics Company Details
 Table 78. AbbVie Therapeutics Business Overview
 Table 79. AbbVie Therapeutics Chronic Pulmonary Hypertension Drug Product
 Table 80. AbbVie Therapeutics Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 81. AbbVie Therapeutics Recent Development
 Table 82. Insmed Company Details
 Table 83. Insmed Business Overview
 Table 84. Insmed Chronic Pulmonary Hypertension Drug Product
 Table 85. Insmed Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 86. Insmed Recent Development
 Table 87. Altavant Sciences Company Details
 Table 88. Altavant Sciences Business Overview
 Table 89. Altavant Sciences Chronic Pulmonary Hypertension Drug Product
 Table 90. Altavant Sciences Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 91. Altavant Sciences Recent Development
 Table 92. Lupin Company Details
 Table 93. Lupin Business Overview
 Table 94. Lupin Chronic Pulmonary Hypertension Drug Product
 Table 95. Lupin Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 96. Lupin Recent Development
 Table 97. Sun Pharmaceutical Company Details
 Table 98. Sun Pharmaceutical Business Overview
 Table 99. Sun Pharmaceutical Chronic Pulmonary Hypertension Drug Product
 Table 100. Sun Pharmaceutical Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 101. Sun Pharmaceutical Recent Development
 Table 102. Teva Company Details
 Table 103. Teva Business Overview
 Table 104. Teva Chronic Pulmonary Hypertension Drug Product
 Table 105. Teva Revenue in Chronic Pulmonary Hypertension Drug Business (2020-2025) & (US$ Million)
 Table 106. Teva Recent Development
 Table 107. Research Programs/Design for This Report
 Table 108. Key Data Information from Secondary Sources
 Table 109. Key Data Information from Primary Sources
 Table 110. Authors List of This Report


List of Figures
 Figure 1. Chronic Pulmonary Hypertension Drug Picture
 Figure 2. Global Chronic Pulmonary Hypertension Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Chronic Pulmonary Hypertension Drug Market Share by Type: 2024 VS 2031
 Figure 4. Oral Features
 Figure 5. Intravenous/Subcutaneous Features
 Figure 6. Inhalational Features
 Figure 7. Global Chronic Pulmonary Hypertension Drug Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Chronic Pulmonary Hypertension Drug Market Share by Application: 2024 VS 2031
 Figure 9. Hospital Pharmacy Case Studies
 Figure 10. Retail Pharmacy Case Studies
 Figure 11. Online Pharmacy Case Studies
 Figure 12. Chronic Pulmonary Hypertension Drug Report Years Considered
 Figure 13. Global Chronic Pulmonary Hypertension Drug Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Chronic Pulmonary Hypertension Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Chronic Pulmonary Hypertension Drug Market Share by Region: 2024 VS 2031
 Figure 16. Global Chronic Pulmonary Hypertension Drug Market Share by Players in 2024
 Figure 17. Global Top Chronic Pulmonary Hypertension Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Pulmonary Hypertension Drug as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Chronic Pulmonary Hypertension Drug Revenue in 2024
 Figure 19. North America Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Chronic Pulmonary Hypertension Drug Market Share by Country (2020-2031)
 Figure 21. United States Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Chronic Pulmonary Hypertension Drug Market Share by Country (2020-2031)
 Figure 25. Germany Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Chronic Pulmonary Hypertension Drug Market Share by Region (2020-2031)
 Figure 33. China Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Chronic Pulmonary Hypertension Drug Market Share by Country (2020-2031)
 Figure 41. Mexico Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Chronic Pulmonary Hypertension Drug Market Share by Country (2020-2031)
 Figure 45. Turkey Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Chronic Pulmonary Hypertension Drug Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Bayer Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 49. Attgeno Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 50. Cereno Scientific Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 51. Bial - Portela C S.A Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 52. Liquidia Technologies Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 53. Bellerophon Therapeutics Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 54. AbbVie Therapeutics Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 55. Insmed Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 56. Altavant Sciences Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 57. Lupin Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 58. Sun Pharmaceutical Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 59. Teva Revenue Growth Rate in Chronic Pulmonary Hypertension Drug Business (2020-2025)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Chronic Pulmonary Hypertension Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pulmonary Hypertension Drug Market Research Report 2025
Hypertension Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Thromboembolic Pulmonary Hypertension Market Research Report 2024
Hypertension Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Blood Pressure Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pulmonary Fibrosis Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Chronic Obstructive Pulmonary Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pulmonary Arterial Hypertension PAH Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pulmonary Embolism Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Essential Hypertension Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pulmonary Arterial Hypertension PAH Drugs Market Research Report 2025
Vasoconstrictor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pulmonary Arterial Hypertension Equipment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pulmonary Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
COPD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Cardiogenic Shock Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Treprostinil Drugs Market Insights Forecast to 2030
Chronic Heart Failure CHF Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Heart Failure Therapeutics Market Research Report 2024

RELATED REPORTS

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Cardiovascular Informations (CVIS) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10A6248
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8I7059
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Heparin Calcium Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15Y8668
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions